131 related articles for article (PubMed ID: 10891474)
21. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
[TBL] [Abstract][Full Text] [Related]
22. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
23. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression.
Ohyashiki K; Ohyashiki JH; Iwama H; Hayashi S; Shay JW; Toyama K
Leukemia; 1997 Feb; 11(2):190-4. PubMed ID: 9009079
[TBL] [Abstract][Full Text] [Related]
24. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
25. Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease.
Sagayadan GE; Wiernik PH; Sun N; Ahearn G; Thompson D; Hallam SJ; Hu XP; Dutcher JP; Gallagher RE
Leuk Res; 1994 Oct; 18(10):741-8. PubMed ID: 7934131
[TBL] [Abstract][Full Text] [Related]
26. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
28. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia.
Ohyashiki K; Iwama H; Tauchi T; Shimamoto T; Hayashi S; Ando K; Kawakubo K; Ohyashiki JH
Leuk Lymphoma; 2000 Dec; 40(1-2):49-56. PubMed ID: 11426628
[TBL] [Abstract][Full Text] [Related]
29. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Maschan A; Novichkova G; Miakova N; Persiantseva M
Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
[TBL] [Abstract][Full Text] [Related]
30. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
31. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
32. Accelerated and blastic phases of chronic myelogenous leukemia.
Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM
Hematol Oncol Clin North Am; 2004 Jun; 18(3):753-74, xii. PubMed ID: 15271404
[TBL] [Abstract][Full Text] [Related]
33. ABL amplification in a patient with lymphoid blast crisis of chronic myelogenous leukaemia.
Kenner L; Beham-Schmid C; Kerbl R; Schmidt HH; Sill H; Hoefler G
Virchows Arch; 1999 Mar; 434(3):255-7. PubMed ID: 10190307
[TBL] [Abstract][Full Text] [Related]
34. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
[TBL] [Abstract][Full Text] [Related]
35. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Brummendorf TH; Ersoz I; Hartmann U; Balabanov S; Wolke H; Paschka P; Lahaye T; Berner B; Bartolovic K; Kreil S; Berger U; Gschaidmeier H; Bokemeyer C; Hehlmann R; Dietz K; Lansdorp PM; Kanz L; Hochhaus A
Ann N Y Acad Sci; 2003 May; 996():26-38. PubMed ID: 12799279
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
37. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
38. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U; Balabanov S; Bali D; Dierlamm J; Braig M; Hartmann U; Sirma H; Günes C; Wege H; Fehse B; Gontarewicz A; Dikomey E; Borgmann K; Brümmendorf TH
Exp Hematol; 2011 Jan; 39(1):66-76.e1-2. PubMed ID: 20940029
[TBL] [Abstract][Full Text] [Related]
39. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Kantarjian HM; Shan J; Smith T; Talpaz M; Kozuch P; Rios MB; Cortes J; Giles FJ; O'Brien S
Cancer; 2001 Nov; 92(10):2501-7. PubMed ID: 11745182
[TBL] [Abstract][Full Text] [Related]
40. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
